Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Ninth European International Kidney Cancer Symposium /
Discussion: Additional treatment options impact first-line treatment of mRCC

25th - 26th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.09.14
Views: 2364

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

The panel discusses points raised by Prof Oudard and Prof Schöffski in their earlier presentations at EIKCS 2014.

Among others, questions such as "What criteria should be used when selecting first-line treatment and/or when assessing which treatment is appropriate?", "Should the drug’s adverse event profile and the patient’s quality of life also be considered?" and "Do we need more first-line agents and/or more decision tools to enhance the success of individualised treatment to extend the benefits of treatment to all patient subgroups?" will be considered.

GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the chairs & speakers and provided input into the symposium agenda/content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation